TradeFlare's AI research teams analysed ROIV on 14 market nights between April 14, 2026 and October 1, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 1, 2026 | HOLD | $36.57 | $44.00 / $30.00 | -3.6% | not yet | The technicals are neutral to bearish in the short term, suggesting a need to wait for a clearer signal. |
| September 29, 2026 | HOLD | $36.98 | $42.53 / $31.43 | -2.7% | not yet | The stock is in a neutral market environment with conflicting technical and fundamental signals, requiring a wait-and-see approach. |
| September 24, 2026 | HOLD | $36.82 | — / — | -1.7% | not yet | The current setup does not warrant a buy. |
| September 23, 2026 | HOLD | $38.22 | — / — | -0.7% | not yet | The current setup does not warrant a BUY. |
| September 22, 2026 | HOLD | $38.99 | $44.84 / $33.14 | -4.5% | not yet | The stock is in a neutral market regime and the technicals are not strongly bullish, suggesting a need for patience. |
| September 21, 2026 | HOLD | $39.77 | — / — | -5.2% | not yet | The current technical setup does not provide a clear entry point, and the high risk score warrants caution. |
| September 18, 2026 | HOLD | $39.98 | $44.00 / $33.98 | -10.0% | not yet | The stock is consolidating near resistance, and a clear breakout is needed before initiating a long position. |
| September 11, 2026 | BUY | $40.94 | $47.08 / $34.70 | -2.6% | -13.2% | The bullish technical setup and fundamental catalysts suggest a medium-term upward trend. |
| September 10, 2026 | BUY | $41.81 | $50.17 / $35.54 | -2.3% | -16.4% | The technical uptrend and positive sentiment suggest a near-term upward move, but the high risk necessitates a shorter horizon. |
| July 29, 2026 | BUY | $33.84 | — / — | +5.3% | +11.8% | Potential for positive clinical trial data or regulatory approvals. |
| June 26, 2026 | BUY | $34.02 | $37.42 / $30.62 | +3.9% | +1.9% | The stock is near its 52-week high and showing momentum, suggesting a short-to-medium term upward trend. |
| June 25, 2026 | BUY Published signal · reached target +10.5% |
$34.01 | — / — | +3.3% | +2.9% | The current market regime and stock-specific technicals do not support a new entry. |
| May 21, 2026 | BUY | $32.41 | — / — | -2.9% | +1.2% | Positive news sentiment driven by Moderna settlement. |
| April 14, 2026 | BUY | $28.95 | $33.75 / $27.24 | +0.6% | +0.9% | The fundamental analysis suggests a medium-term upside based on analyst price targets. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.